Share This

Related Topics News - Drugs

     
 Title only   |   Print    Next page > 
     
石藥集團旗下流感藥物通過國家藥監局一致性評價

2024-05-14T  
金斯瑞附屬傳奇生物首季虧損收窄至5,979萬美元

2024-05-14T  
上海醫藥注射用藥品獲生產批准

2024-05-14T  
中生製藥旗下肺癌藥物獲國家藥監局批准上市

2024-05-09T  
《大行》大摩升石藥集團目標價至12元 評級「增持」

2024-05-09T  
上海醫藥左西孟旦注射液獲批生產

2024-05-06T  
上海醫藥:注射用帕瑞昔布鈉新增規格獲內地批准

2024-05-02T  
中國生物製藥一款自主研究新藥獲批上市

2024-04-30T  
石藥受託人根據股份獎勵計劃購479萬股

2024-04-26T  
《業績》上海醫藥首季純利15.42億元人民幣 按年升1.6%

2024-04-26T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.